Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | LMNA | P02545 | 4/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | BDKRB1 | P46663 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4111436 | 0.93 | BDKRB1 (0.41) | NPSR1TSHRALDH1A1MEN1KMT2A | |
| SCHEMBL5132291 | 0.89 | NPSR1 (0.43) | NPSR1TSHRALDH1A1LMNAMAPT | |
| SCHEMBL5132127 | 0.86 | EPHX2 (0.46) | NPSR1TSHRALDH1A1LMNAMAPT | |
| SCHEMBL4117203 | 0.84 | TSHR (0.43) | NPSR1TSHRALDH1A1LMNAMAPT | |
| SCHEMBL4124553 | 0.83 | BDKRB1 (0.40) | NPSR1TSHRALDH1A1MEN1KMT2A | |
| SCHEMBL4119445 | 0.83 | EPHX2 (0.49) | MEN1KMT2A | |
| SCHEMBL5125343 | 0.83 | BDKRB1 (0.39) | NPSR1TSHRALDH1A1MEN1KMT2A | |
| SCHEMBL2833249 | 0.81 | TSHR (0.46) | NPSR1TSHRALDH1A1LMNAMAPT | |
| SCHEMBL5122612 | 0.80 | BDKRB1 (0.45) | BDKRB1 | |
| SCHEMBL5128634 | 0.80 | EPHX2 (0.42) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090253669-A1 | Substituted Sulfonamide Compounds | GRUENENTHAL GMBH (DE) | 2009-10-08 | — | — | US | disclosed |
| US-20090253669-A1 | Substituted Sulfonamide Compounds | GRUENENTHAL GMBH (DE) | 2009-10-08 | — | — | US | disclosed |
| US-20090253669-A1 | Substituted Sulfonamide Compounds | GRUENENTHAL GMBH (DE) | 2009-10-08 | — | — | US | disclosed |
| US-20080306084-A1 | Substituted Amide Compounds | GRUENENTHAL GMBH (DE) | 2008-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080306084-A1 | Substituted Amide Compounds | OPRK1, NAA50, ACMSD | NPSR1 371/4885TSHR 4051/4885ALDH1A1 1349/4885 |
| US-20090253669-A1 | Substituted Sulfonamide Compounds | SULT2A1, STS, SULT1A1 | NPSR1 394/4885TSHR 3282/4885ALDH1A1 863/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.